Risk stratification for Sudden Cardiac Death (SCD)
Medilec's innovative EP technology benefits from extensive published academic clinical research and derives from British Heart Foundation (BHF) funded research at St Georges Hospital, London. This was then followed by commercial research conducted in collaboration with Papworth Hospital and the University of Cambridge.
The cardiac technology has benefited from a number of development stages, some of which have been funded by the British Heart Foundation (BHF) and the UK Department of Health MedLINK programme.
Shareholders in Medilec include the director (Dr Barfoot), Papworth Hospital NHS Trust, the University of Cambridge, and Staplethorne Ltd.
Medilec is now seeking a commercial partner to help bring the cardiac technology to market. Medilec would also consider other forms of collaboration.
It is anticipated that there would be a number of further stages of development:
1) Complete the development and CE-marking of a commercial product for non-coronary market use, and to locate it in a clinical user setting as a point of reference.
2) Commercially launchin Europe for non-coronary applications (i.e. for patients who are born with the 'substrate' for SCD, rather than those who develop it following coronary problems).
3) Clinical trials (mostly in the USA) in post-coronary applications and in gaining FDA approvals for both non-coronary and coronary use.
Staplethorne Ltd has continuing involvement with the further development of Medilec Ltd.
Further information on Medilec Ltd can be found at www.pefa.co.uk.